21-Aug-2026
BioCryst Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
BioCryst to Report Second Quarter 2026 Financial Results on August 5
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Globe Newswire (Wed, 15-Jul 7:00 AM ET)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Jul 7:00 AM ET)
Globe Newswire (Mon, 29-Jun 7:00 AM ET)
Market Chameleon (Fri, 12-Jun 3:08 AM ET)
Globe Newswire (Fri, 12-Jun 7:00 AM ET)
Globe Newswire (Wed, 27-May 7:00 AM ET)
BioCryst Leverages ORLADEYO Growth and Strategic Partnerships to Strengthen Rare Disease Focus
Market Chameleon (Wed, 6-May 3:40 AM ET)
Market Chameleon (Thu, 26-Feb 2:43 AM ET)
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Biocryst Pharmaceuticals trades on the NASDAQ stock market under the symbol BCRX.
As of August 21, 2026, BCRX stock price declined to $9.55 with 2,336,812 million shares trading.
BCRX has a beta of 0.15, meaning it tends to be less sensitive to market movements. BCRX has a correlation of 0.00 to the broad based SPY ETF.
BCRX has a market cap of $2.44 billion. This is considered a Mid Cap stock.
Last quarter Biocryst Pharmaceuticals reported $218 million in Revenue and $.30 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.08.
In the last 3 years, BCRX traded as high as $11.31 and as low as $4.03.
The top ETF exchange traded funds that BCRX belongs to (by Net Assets): XBI, VTI, IWM, VB, VXF.
BCRX has underperformed the market in the last year with a return of +14.0%, while SPY returned +21.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BCRX shares. However, BCRX has outperformed the market in the last 3 month and 2 week periods, returning +14.1% and +1.8%, while SPY returned +3.4% and -1.0%, respectively. This indicates BCRX has been having a stronger performance recently.
BCRX support price is $9.35 and resistance is $9.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCRX shares will trade within this expected range on the day.